South Korea · Delayed Price · Currency is KRW Samsung Life Insurance Earnings Call Transcripts
Fiscal Year 2026
-
Net profit surged 35.8% year-on-year to KRW 1.9 trillion, driven by strong investment income, while insurance service results declined due to higher claims and one-off expenses. New business CSM grew 20% and capital adequacy remains robust, with a continued focus on dividend growth and overseas expansion.
-
Q1 2026 net income rose 89.5% YoY to KRW 1,203.6B, with strong CSM growth and a 210% K-ICS ratio. Health products now make up 60% of the portfolio, and the company remains committed to stable DPS growth and disciplined capital allocation.
Fiscal Year 2025
-
Net profit for FY2025 rose 9.3% to KRW 2.3 trillion, with record CSM growth and strong health product sales. Dividend per share increased 18%, and the company targets further CSM and DPS growth in 2026 amid regulatory and market changes.
-
New business CSM and net profits grew year-over-year, driven by health product expansion and improved investment yields. RBC ratio strengthened, and the company remains focused on high-margin products, stable CSM growth, and shareholder returns.
-
Net profit rose 1.9% year-on-year to KRW 1.394 trillion in H1 2025, driven by robust health insurance growth and strong CSM performance. KICS ratio improved to 187%, with a focus on maintaining capital adequacy and increasing shareholder returns.
-
Net profit rose 2.1% year-over-year to ₩635.3 billion in Q1 2025, driven by strong health segment growth and investment gains. The K-ICS ratio remains robust at 180%, with a focus on expanding shareholder returns and maintaining capital adequacy despite regulatory and market volatility.
Fiscal Year 2024
-
Record net profit and strong health product sales drove growth, with a focus on capital soundness and higher dividends. K-ICS ratio is expected to remain robust despite market headwinds, and a 50% payout ratio is targeted within four years.
-
Q3 saw robust growth in health product sales, boosting new business CSM and net profit. Solvency ratios are being recalibrated amid regulatory changes, with capital management and dividend policy under review. Strategic focus is shifting toward senior and healthcare business.
-
Net profit surged 40.5% year-on-year in H1 2024, driven by strong insurance and investment results. Health products now make up 54% of new business CSM, and the company targets a 50% shareholder payout ratio within 3–4 years, pending regulatory changes.